Investigators of a study assessed efficacy outcomes in 989 patients who were randomized to receive bimekizumab treatment through 3 years. Data were pooled from 52-week (BE VIVID) and 56-week (BE READY and BE SURE) phase 3 studies, as well as the ongoing open-label extension (OLE), BE BRIGHT. Modified nonresponder imputation (mNRI) were used for missing data.
A total of 693 patients met ≥90% reduction from baseline in Psoriasis Area and Severity Index (PASI 90), 503 met 100% reduction from baseline in PASI (PASI 100), 694 met absolute PASI ≤2, and 597 met body surface area (BSA) ≤1% at Week 16, and were able to continue to the OLE. These patients continued to receive treatment for 3 years, with 93.0% maintaining PASI 90, 80.8% maintaining PASI 100, 94.0% maintaining PASI ≤2, and 90.3% maintaining BSA ≤1% responses (mNRI). Approximately 96.8% and 72.5% met Investigator’s Global Assessment (IGA) 0/1 and PASI 100 at Week 16, respectively, and 92.2% and 73.4% saw these responses at Year 3 (mNRI) among those who were PASI 90 responders at Week 16. Approximately 76.3% also met Dermatology Life Quality Index (DLQI) 0/1 at Week 16, with DLQI 0/1 response continuing to increase with treatment with bimekizumab to 89.0% at Year 3 (mNRI).
Reference: Strober B, Tada Y, Mrowietz U, et al. Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial [published online ahead of print, 2023 Mar 27]. Br J Dermatol. 2023;ljad035. doi:10.1093/bjd/ljad035